Citadel Advisors
KLRA

Citadel Advisors’s Kailera Therapeutics KLRA Stock Holding History

Citadel Advisors’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.4M Buy
+3,240,787
New +$71.2M 0.01% 1237

Other funds holding KLRA

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Citadel Advisors's KLRA Position: Q2 2026 in Review

Citadel Advisors opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 3,240,787 shares worth $71.4M. The stake represents 0.01% of the portfolio and ranks #1237 among its holdings.

91 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • Citadel Advisors held 3,240,787 shares of Kailera Therapeutics worth $71.4M as of Q2 2026.
  • Kailera Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Kailera Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #1237 holding.
  • 91 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.